These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15187802)

  • 1. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
    Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
    J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder.
    Riggs PD; Leon SL; Mikulich SK; Pottle LC
    J Am Acad Child Adolesc Psychiatry; 1998 Dec; 37(12):1271-8. PubMed ID: 9847499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.
    Riggs PD; Thompson LL; Mikulich SK; Whitmore EA; Crowley TJ
    J Am Acad Child Adolesc Psychiatry; 1996 Aug; 35(8):1018-24. PubMed ID: 8755798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study.
    Heiligenstein E; Johnston HF; Nielsen JK
    J Am Coll Health; 1996 Jul; 45(1):35-9. PubMed ID: 8708264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
    Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
    Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J; Pliszka SR
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.